Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence

Biological Psychiatry

Volumn 72, Issue 10, 2012, Pages 832-838

  Fucito, Lisa M ^a   Park, Aesoon ^d   Gulliver, Suzy Bird ^e,f   Mattson, Margaret E ^g,h   Gueorguieva, Ralitza V ^c   O'Malley, Stephanie S ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c YALE UNIVERSITY   (United States)

^d SYRACUSE UNIVERSITY   (United States)

^e VA VISN 17 Center of Excellence for Research on Returning War Veterans   (United States)

^f Central Texas Veteran's Health Care System   (United States)

^g NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^h SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

Author keywords

Acamprosate; alcohol dependence; behavioral treatment; cigarette smoking; naltrexone; pharmacotherapy

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ADULT; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; COMORBIDITY; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; SMOKING; TAURINE; TREATMENT OUTCOME;

EID: 84867748661     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2012.03.023     Document Type: Article

References (51)

1. H.R. Kranzler, J. Van Kirk Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis Alcohol Clin Exp Res 25 2001 1335 1341
2. H.M. Pettinati, A.R. Rabinowitz Choosing the right medication for the treatment of alcoholism Curr Psychiatry Rep 8 2006 383 388
3. H.C. Kraemer, G.T. Wilson, C.G. Fairburn, W.S. Agras Mediators and moderators of treatment effects in randomized clinical trials Arch Gen Psychiatry 59 2002 877 883
4. R.F. Anton, G. Oroszi, S. O'Malley, D. Couper, R. Swift, H. Pettinati An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study Arch Gen Psychiatry 65 2008 135 144
5. M.P. Bogenschutz, J. Scott Tonigan, H.M. Pettinati Effects of alcoholism typology on response to naltrexone in the COMBINE study Alcohol Clin Exp Res 33 2009 10 18
6. G. Rubio, G. Ponce, R. Rodriguez-Jimenez, M.A. Jimenez-Arriero, J. Hoenicka, T. Palomo Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol Alcohol 40 2005 227 233
7. J.W. Tidey, P.M. Monti, D.J. Rohsenow, C.J. Gwaltney, R. Miranda Jr, J.E. McGeary Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment Alcohol Clin Exp Res 32 2008 58 66
8. S. Ball Type A and type B alcoholism applicability across subpopulations and treatment settings Alcohol Health Res World 20 1996 30 35
9. J. Gelernter, H. Kranzler, J. Cubells Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: Population studies, and allele frequencies in alcohol- and drug-dependent subjects Mol Psychiatry 4 1999 476 483
10. B.F. Grant, D.S. Hasin, S.P. Chou, F.S. Stinson, D.A. Dawson Nicotine dependence and psychiatric disorders in the United States: Results from the national epidemiologic survey on alcohol and related conditions Arch Gen Psychiatry 61 2004 1107 1115
11. S.A. McKee, T. Falba, S.S. O'Malley, J. Sindelar, P.G. O'Connor Smoking status is a clinical indicator for alcohol misuse in US adults Arch Intern Med 167 2007 716 721
12. M.C. Fiore, C.R. Jaen, T.B. Baker, W.C. Bailey, N.L. Benowitz, S.J. Curry Treating Tobacco Use and Dependence, 2008 Update Clinical Practice Guideline 2008 US Department of Health and Human Services Rockville, MD
13. D.B. Abrams, D.J. Rohsenow, R.S. Niaura, M. Pedrazac, R. Longabaugh, M.C. Beattiee Smoking and treatment outcome for alcoholics: Effects on coping skills, urge to drink, and drinking rates Behav Ther 23 1992 283 297
14. T. Hintz, K. Mann Long-term behavior in treated alcoholism: Evidence for beneficial carry-over effects of abstinence from smoking on alcohol use and vice versa Addict Behav 32 2007 3093 3100
15. A. King, D. Cao, C. Vanier, T. Wilcox Naltrexone decreases heavy drinking rates in smoking cessation treatment: An exploratory study Alcohol Clin Exp Res 33 2009 1044 1050
16. S.S. O'Malley, S. Krishnan-Sarin, S.A. McKee, R.F. Leeman, N.L. Cooney, B. Meandzija Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation Int J Neuropsychopharmacol 12 2009 589 597
17. B.J. Mason, P. Lehert Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy J Addict Med 3 2009 164 171
18. D. Kalman, S. Kim, G. DiGirolamo, D. Smelson, D. Ziedonis Addressing tobacco use disorder in smokers in early remission from alcohol dependence: The case for integrating smoking cessation services in substance use disorder treatment programs Clin Psychol Rev 30 2010 12 24
19. J.J. Prochaska, K. Delucchi, S.M. Hall A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery J Consult Clin Psychol 72 2004 1144 1156
20. D.A. Baltieri, F.R. Daro, P.L. Ribeiro, A.G. Andrade Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients Drug Alcohol Depend 105 2009 33 41
21. D.J. Rohsenow, P.M. Monti, S.M. Colby, S.B. Gulliver, R.M. Swift, D.B. Abrams Naltrexone treatment for alcoholics: Effect on cigarette smoking rates Nicotine Tob Res 5 2003 231 236
22. R.F. Anton, S.S. O'Malley, D.A. Ciraulo, R.A. Cisler, D. Couper, D.M. Donovan Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial JAMA 295 2006 2003 2017
23. S.S. O'Malley, J.C. Froehlich Advances in the use of naltrexone: An integration of preclinical and clinical findings Recent Dev Alcohol 16 2003 217 245
24. J.S. Tonigan, W.R. Miller, J.M. Brown The reliability of Form 90: An instrument for assessing alcohol treatment outcome J Stud Alcohol 58 1997 358 364
25. L.C. Sobell, M.B. Sobell Alcohol Consumption Measures 2003 National Institute on Alcohol Abuse and Alcoholism Bethesda, MD
26. K.B. Friend, M.E. Pagano Changes in cigarette consumption and drinking outcomes: Findings from Project MATCH J Subst Abuse Treat 29 2005 221 229
27. W.R. Miller, J.S. Tonigan, R. Longabaugh The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse 1995 National Institutes of Health Rockville, MD
28. M.B. First, R.L. Spitzer, M. Gibbon, J.B.W. Williams Structured Clinical Interview for DSM-IV-TR Axis I Disorders Research Version 2002 State Psychiatric Institute New York
29. H. Skinner, J. Horn Alcohol Dependence Scale: User's Guide 1984 Addiction Research Foundation Toronto
30. G.M. Fitzmaurice, N.M. Laird, J.H. Ware Applied Longitudinal Analysis 2004 Wiley Hoboken, NJ
31. L.G. Schmidt, M.N. Smolka Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers Alcohol Alcohol 42 2007 241 246
32. K.B. Friend, M.E. Pagano Smoking cessation and alcohol consumption in individuals in treatment for alcohol use disorders J Addict Dis 24 2005 61 75
33. N.L. Cooney, J.L. Cooney, B.L. Perry, M. Carbone, E.H. Cohen, H.R. Steinberg Smoking cessation during alcohol treatment: A randomized trial of combination nicotine patch plus nicotine gum Addiction 104 2009 1588 1596
34. S.A. McKee, E.L. Harrison, S.S. O'Malley, S. Krishnan-Sarin, J. Shi, J.M. Tetrault Varenicline reduces alcohol self-administration in heavy-drinking smokers Biol Psychiatry 66 2009 185 190
35. L.M. Fucito, B.A. Toll, R. Wu, D.M. Romano, E. Tek, S.S. O'Malley A preliminary investigation of varenicline for heavy drinking smokers Psychopharmacology 215 2011 655 663
36. B.A. Johnson, N. Ait-Daoud, F.Z. Akhtar, M.A. Javors Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: A randomized controlled trial Arch Intern Med 165 2005 1600 1605
37. J.R. Monterosso, B.A. Flannery, H.M. Pettinati, D.W. Oslin, M. Rukstalis, C.P. O'Brien Predicting treatment response to naltrexone: The influence of craving and family history Am J Addict 10 2001 258 268
38. D.J. Rohsenow, R. Miranda Jr, J.E. McGeary, P.M. Monti Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics Exp Clin Psychopharmacol 15 2007 272 281
39. F. Kiefer, H. Helwig, T. Tarnaske, C. Otte, H. Jahn, K. Wiedemann Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome Eur Addict Res 11 2005 83 91
40. E.C. Donny, A.R. Caggiula, M.T. Weaver, M.E. Levin, A.F. Sved The reinforcement-enhancing effects of nicotine: Implications for the relationship between smoking, eating, and weight Physiol Behav 104 2011 143 148
41. E. Löf, P. Olausson, A. deBejczy, R. Stomberg, J.M. McIntosh, J.R. Taylor Nicotinic acetylcholine receptors in the ventral tegmental area mediate the dopamine activating and reinforcing properties of ethanol cues Psychopharmacology 195 2007 333 343
42. C. Chiamulera Cue reactivity in nicotine and tobacco dependence: A "multiple-action" model of nicotine as a primary reinforcement and as an enhancer of the effects of smoking-associated stimuli Brain Res Rev 48 2005 74 97
43. J.M. Trigo, E.M. García, F. Berrendero, P. Robledo, R. Maldonado The endogenous opioid system: A common substrate in drug addiction Drug Alcohol Depend 108 2010 183 194
44. Y.S. Mineur, A. Abizaid, Y. Rao, R. Salas, R.J. DiLeone, D. Gündisch Nicotine decreases food intake through activation of POMC neurons Science 332 2011 1330 1332
45. T. Frech, K. Novak, M.P. Revelo, M. Murtaugh, B. Markewitz, N. Hatton Low-dose naltrexone for pruritus in systemic sclerosis Int J Rheumatol 2011 2011 804296
46. N. Brown, J. Panksepp Low-dose naltrexone for disease prevention and quality of life Med Hypotheses 72 2009 333 337
47. P. Mannelli, K. Peindl, A.A. Patkar, L.T. Wu, H.M. Tharwani, D.A. Gorelick Problem drinking and low-dose naltrexone-assisted opioid detoxification J Stud Alcohol Drugs 72 2011 507 513
48. J.P. Smith, H. Stock, S. Bingaman, D. Mauger, M. Rogosnitzky, I.S. Zagon Low-dose naltrexone therapy improves active Crohn's disease Am J Gastroenterol 102 2007 820 828
49. E.M. Lee, J.L. Malson, A.J. Waters, E.T. Moolchan, W.B. Pickworth Smoking topography: Reliability and validity in dependent smokers Nicotine Tob Res 5 2003 673 679
50. G. Scherer Smoking behaviour and compensation: A review of the literature Psychopharmacology 145 1999 1 20
51. C. Pelucchi, S. Gallus, W. Garavello, C. Bosetti, C. La Vecchia Cancer risk associated with alcohol and tobacco use: Focus on upper aero-digestive tract and liver Alcohol Res Health 29 2006 193 198